Jun 29, 2026
Two studies published in Nature Medicine and Military Medical Research link accelerated biological aging in younger generations to rising rates of early-onset cancers. Researchers found that people born in more recent decades show larger gaps between their chronological and biological ages, with stronger risks for lung, gastrointestinal, and uterine cancers. A separate global analysis identified six cancers now rising faster in younger adults than older populations.
May 18, 2026
A real-world analysis found BRAF V600E-mutated papillary thyroid cancer had a proinflammatory molecular profile, but no significant overall survival difference versus BRAF wild-type disease. Treatment choice among BRAF/MEK inhibitors, tyrosine kinase inhibitors, and immunotherapy was not associated with significant survival differences.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Mar 13, 2026
Bariatric surgery procedures have fallen 46.4% since 2022 as prescriptions for semaglutide and tirzepatide rose to 24.17% of eligible adults by Q3 2025, though 75.8% of eligible patients still receive no treatment.
Mar 13, 2026
Recent studies examine safety profiles of GLP-1 receptor agonists, finding increased risk for nonscarring hair loss but improved survival in patients with brain metastases and type 2 diabetes.
Mar 04, 2026
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
Feb 17, 2026
Phase 3 LIBRETTO-432 trial met its primary endpoint, showing selpercatinib delivered statistically significant and clinically meaningful improvement in event-free survival versus placebo as adjuvant therapy in early-stage RET fusion-positive NSCLC.
